Salvage treatment with paclitaxel and gemcitabine for patients with non- small-cell lung cancer after cisplatin- or docetaxel-based chemotherapy: A multicenter phase II study

Annals of Oncology

Volumn 9, Issue 10, 1998, Pages 1127-1130

  Androulakis, N ^a   Kouroussis, C ^a   Kakolyris, S ^a   Tzannes, S ^b   Papadakis, E ^b   Papadimitriou, C ^c   Geroyianni, A ^b   Georgopoulou, T ^b   Dimopoulou, I ^c   Souglakos, J ^a   Kotsakis, A ^a   Vardakis, N ^a   Hatzidaki, D ^a   Georgoulias, V ^a,d  

^a UNIVERSITY OF CRETE   (Greece)

^b IASO GENERAL HOSPITAL   (Greece)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^d UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Gemcitabine; Non small cell lung cancer; Paclitaxel; Phase II trial

Indexed keywords

CISPLATIN; DOCETAXEL; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; NAVELBINE; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; MALE; NEUROTOXICITY; NEUTROPENIA; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 7844245430     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008497322508     Document Type: Article

References (12)

1. Rowinsky EK, Donehower RC Paclitaxel (Taxol). N Engl J Med 1995; 332: 1004-14.
2. Chang AY, Kim K, Glick J et al. Phase 11 study of Taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: The Easten Cooperative Group results. J Natl Cancer Inst 1993; 85: 388-94.
3. Murphy WK, Fossella FV, Winn RJ et al. Phase II study of Taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst 1993; 85: 384-7.
4. Tan V, Herrera C, Einzroj AI et al. Taxol is active as a three-hour or 24-hour infusion in non-small-cell lung cancer. Proc Am Soc Clin Oncol 1995; 14: 366 (Abstr).
5. Hainsworth JD, Thompson DS, Greco AF. Paclitaxel by one-hour infusion: An active drug in metastatic non-small-cell lung cancer. J Clin Oncol 1995; 13: 1609-14.
6. Abratt RP, Bezwoda WR, Falkson G et al. Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: A phase II study. J Clin Oncol 1994; 12: 1535-40.
7. Anderson H, Lund B, Bach F et al. Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: A phase II study. J Clin Oncol 1994; 12: 1821 6.
8. Gatzemeir H, Sheperd FA, Le Chevalier T et al. Activity of gemcitabine in patients with non-smal-cell lung cancer: A multicentre, extended phase II study. Eur J Cancer 1996; 34A: 243-8.
9. Crino L, Mosconi AM, Scagliotti G et al. Salvage therapy with gemcitabine in pretreated, advanced non-small-cell lung cancer. Proc Am Soc Clin Oncol 1997; 16: 1603 (Abstr).
10. Plunkett W, Huang P, Searcy CE, Gandhi V. Gemcitabine: Preclinical pharmacology and mechanisms of action. Semin Oncol 1996; 23 (Suppl 10): 3-15.
11. Miller AB, Hoogstraten B, Staguet M et al. Reporting results of cancer research. Cancer 1981; 47: 207-14.
12. Poole CJ, Perren T, Hogberg T et al. A phase I study to investigate alternate sequencing of the combination of gemcitabine and paclitaxel in ovarian carcinoma. Eur J Cancer 1997; 33 (Suppl 8): 543 (Abstr).